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http://dxObjectives: The presence of postoperative atrial fibrillation predicts a higher short- and long-term mortality
rates; however, no scoring system has been used to discriminate patients at high risk for this complication.
The aim of this study was to investigate whether the CHADS2 and CHA2DS2-VASc scores are useful risk
assessment tools for new-onset atrial fibrillation after cardiac surgery.
Methods:A total of 277 consecutive patients who underwent cardiac surgery were prospectively included in this
risk stratification study. We calculated the CHADS2 and CHA2DS2-VASc scores from the data collected. The
primary end point was the development of postoperative atrial fibrillation within 30 days after cardiac surgery.
Results: Eighty-four (30%) of the patients had postoperative atrial fibrillation at a median of 2 days (range,
0-27 days) after cardiac surgery. The CHADS2 and CHA2DS2-VASc scores were significant predictors of post-
operative atrial fibrillation in separate multivariate regression analyses. The Kaplan-Meier analysis obtained
a higher postoperative atrial fibrillation rate when based on the CHADS2 and CHA2DS2-VASc scores of at least
2 than when based on scores less than 2 (both log rank, P<.001). In addition, the CHA2DS2-VASc scores could
be used to further stratify the patients with CHADS2 scores of 0 or 1 into 2 groups with different postoperative
atrial fibrillation rates at a cutoff value of 2 (12% vs 32%; P ¼ .01).
Conclusions: CHADS2 and CHA2DS2-VASc scores were predictive of postoperative atrial fibrillation after car-
diac surgery and may be helpful for identifying high-risk patients. (J Thorac Cardiovasc Surg 2013;146:919-26)Supplemental material is available online.
Atrial fibrillation (AF) occurs in 205 to 40% of patients
undergoing cardiac surgery, with the arrhythmia usually
occurring between the second and fourth day after cardiac
surgery.1-3 Studies have demonstrated that various clinical
risk factors, including advanced age, hypertension, left
ventricular (LV) hypertrophy, LV systolic and diastolic
dysfunction, and left atrial function and dimension, are
closely linked to postoperative AF (POAF).4-6 Although
POAF is usually self-limiting, patients with POAF
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Mperioperative morbidity, and greater early and long-term
mortalites.4-7
It is advisable that prophylactic therapy with antiarrhyth-
mic drugs be administered to decrease the incidence of
POAF8,9; however, the use of prophylactic treatment in all
patients to prevent POAF is not cost-effective.2 In addition,
such treatments may have adverse effects. Because the use
of prophylactic therapy for all patients who undergo cardiac
surgery is not reasonable, the identification of patients at
risk for POAF would be helpful.
Use of the CHA2DS2-VASc score (congestive heart failure;
hypertension; age75 years [doubled]; type 2 diabetes; pre-
vious stroke, transient ischemic attack [TIA], or thromboem-
bolism [doubled]; vascular disease; age 65-75 years; and sex
category), which extends the CHADS2 score (congestive
heart failure, hypertension, age 75 years, type 2 diabetes,
and previous stroke or TIA [doubled]) by considering addi-
tional stroke risk factors, was recently recommended to guide
antithrombotic therapy in patientswithAForatrialflutter.10-12
Each component of theCHADS2 andCHA2DS2-VASc scores
has been associated with the ventricular remodeling, LV
diastolic function, and left atrial enlargement that may lead
to atrial arrhythmia13-15; however, no published studies have
investigated the association between the CHADS2 and
CHA2DS2-VASc scores in the prediction of POAF. This
study aimed to assess the CHADS2 and CHA2DS2-VASc
scores for predicting the initiation of new-onset POAF after
cardiac surgery.rdiovascular Surgery c Volume 146, Number 4 919
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
E ¼ early mitral inflow velocity
e0 ¼ medial mitral annular velocity during
passive filling
LV ¼ left ventricular
LVEDD ¼ left ventricular end-diastolic diameter
LVM ¼ left ventricular mass
OR ¼ odds ratio
PAD ¼ peripheral arterial disease
POAF ¼ postoperative atrial fibrillation
PWTD ¼ posterior wall thickness
SWTD ¼ interventricular septal wall thickness
TIA ¼ transient ischemic attack
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Patient Population
This prospective study recruited 340 consecutive patients who under-
went cardiac surgery in our institution between January 2008 and
December 2011. All had preoperative sinus rhythm and underwent iso-
lated coronary artery bypass grafting (CABG), valvular repair or replace-
ment, or both combined and survived the operation. We excluded
patients with a preoperative history of AF, a pacemaker, Cox maze or
radiofrequency ablation procedure for atrial arrhythmia, moderate or se-
vere mitral stenosis or regurgitation, history of myocardial infarction in
recent 3 months, or incomplete diastolic function assessment. A total of
280 patients met the inclusion criteria and were included in the study.
After cardiac surgery, 3 patients who received early antiarrhythmic drugs
for ventricular arrhythmia were excluded from the study. Finally, a total
of 277 patients were enrolled in the study (mean age, 62.1  9.7 years;
213 male).
Clinical reports, echocardiographic reports, carotid ultrasonography,
and complete medical records were prospectively collected to investigate
the relationship among CHADS2, CHA2DS2-VASc score, and the risk of
new-onset POAF after cardiac surgery. This study was approved by the
institutional review board for human subjects at our institution, and the
patients provided written, informed consent before participating in the
study.
CHADS2 and CHA2DS2-VASc Scores
The CHADS2 score was calculated for all the patients by assigning 1
point for each of the following criteria: congestive heart failure, hyperten-
sion, age at least 75 years, and diabetes mellitus. A further 2 points was
added for the criterion of previous stroke or TIA. In contrast, the
CHA2DS2-VASc score is based on a point system in which 2 points each
are assigned for age at least 75 years and for history of stroke, TIA, or
thromboembolism and 1 point is assigned for each of the following criteria:
congestive heart failure, hypertension, diabetesmellitus, age 65 to 75 years,
vascular disease (defined as previous myocardial infarction, complex aortic
plaque, carotid disease, and peripheral arterial disease [PAD], including in-
termittent claudication, previous surgery or percutaneous intervention on
the abdominal aorta or the lower extremity vessels, and arterial and venous
thrombosis), and female sex category.10,11 The cutoff values of the
CHADS2 and CHA2DS2-VASc scores used for grouping were
determined according to risk of stroke and atrial properties determined in
earlier studies.11,16,17920 The Journal of Thoracic and Cardiovascular SurgPOAF Definition
The study defined POAF in the same manner as earlier studies that de-
fined POAF on the basis of documented AF episodes lasting longer than
30 seconds recorded by continuous telemetry throughout hospitalization
or by electrocardiography within the 30-day follow-up period after cardiac
surgery.5,18 A standard 12-lead electrocardiogram was recorded for every
patient who had a suspected arrhythmic event.
Echocardiography
Echocardiography was performed by an experienced sonographer
(S.K.C.) before the index cardiac procedure. Doppler echocardiography
was performed to determine the earlymitral inflow velocity (E), and a tissue
Doppler imaging evaluation was performed to determine the medial mitral
annular velocity during passive filling (e0).19,20 Diastolic dysfunction was
defined as an E/e0 ratio greater than 15, as previously described
elsewhere.20 LV size and wall thickness were determined with M-mode
measurement. The diastolic measurements of LV end-diastolic diameter
(LVEDD), interventricular septal wall thickness (SWTD), and posterior
wall thickness (PWTD, all in millimeters) were used to calculate LV
mass (LVM) in grams according to the formula recommended by the Amer-
ican Society of Echocardiography21:
LVM ¼ 0:81:04ðLVEDD þ SWTD þ PWTDÞ3ðLVEDDÞ3 þ 0:6
The LVM index (in grams per square meter) was defined as LVM
normalized by body surface area.21
Carotid Ultrasonography
The diagnosis of carotid artery stenosis was based on the ultrasono-
graphic analysis, and all carotid ultrasonographic studies were performed
before cardiac surgery. The method of carotid artery stenosis measurement
has been reported previously.22 In brief, the equipment used was a SONOS
5500 ultrasound system (Philips Healthcare, Andover, Mass) equipped
with a 3- to 11-MHz real-time B-mode scanner and a 3.6-MHz pulsed
Doppler mode scanner. Carotid artery segments, including the common ca-
rotid artery, internal carotid artery, and external carotid artery, were mea-
sured bilaterally by an experienced neurologist (L.M.L.) who was
blinded to each subject’s information. The presence of plaques was defined
as localized echo structures encroaching into the arterial lumen of at least
50% of the surrounding intimal media thickness value. The presence of
significant carotid artery stenosis was defined as a large plaque comprising
at least 50% of the diameter of the carotid artery stenosis.Statistics
In this study, we enrolled around 100 patients with risk scale scores of at
least 2 and 170 subjects with scores lower than 2. Our preliminary data in-
dicated that the POAF rate among those with low score would be 20%. If
the true relative risk of subjects with high scores relative to those with low
scores were 2, we would be able to reject the null hypothesis that the rela-
tive risk was equal to 1 with probability (power) of 0.8. The type I error
probability associated with this test of this null hypothesis is 0.05.
Quantitative data are expressed as mean SD and were compared with
2-sample t tests for independent samples. Differences in proportion were
compared with a c2 test or Fisher exact test as appropriate. Univariate as-
sociation of variables with the outcome of POAF within 30 days was as-
sessed with multivariate logistic regression. For each variable, the odds
ratio (OR), 95% confidence interval (CI), and P value are provided. Ex-
ploratory data analyses were conducted with univariate summaries to ex-
amine distributions of key variables. Variables significantly associated
with POAF after univariate analysis (P<.05) and those that were estab-
lished risk factors were entered in a multivariable logistic regression model
to identify the independent predictors of POAF. The POAF-free survival
curves were constructed according to the Kaplan–Meier method. Theery c October 2013
TABLE 1. Baseline characteristics of patients with and without postoperative atrial fibrillation
With POAF (n ¼ 84) Without POAF (n ¼ 193) P value
Age (y) 66.7  9.1 60.2  9.3 <.001
Age 65 y 53 (63.1%) 62 (33.0%) <.001
Age 75 y 22 (26.2%) 14 (7.3%) <.001
Male 64 (76.2%) 149 (77.2%) .86
Body mass index (kg/m2) 25.8  3.9 26.1  3.8 .61
Current smoking 41 (48.8%) 81 (42.0%) .29
Medical history
Hypertension 71 (84.5%) 142 (73.6%) .047
Diabetes mellitus 52 (61.9%) 101 (52.3%) .14
Congestive heart failure 25 (29.8%) 42 (21.8%) .13
Previous stroke or TIA 19 (22.6%) 19 (9.8%) .004
Hyperlipidemia 38 (45.2) 108 (56.0%) .10
Vascular disease* 39 (45.9%) 45 (23.4%) <.001
Previous myocardial infarction 13 (15.5%) 12 (6.2%) .01
Carotid artery stenosisy 17 (20.2%) 30 (15.5%) .32
Peripheral arterial disease 10 (11.9%) 5 (2.6%) <.001
Preoperative medication
b-Blockers 38 (64%) 161 (74%) .15
ACEIs or ARBs 35 (59%) 132 (61%) .87
Calcium channel blockers 16 (19%) 36 (19%) .94
Statin therapies 28 (47%) 124 (57%) .20
Diuretics 30 (36%) 54 (28%) .20
Aspirin 46 (55%) 111 (58%) .67
Clopidogrel 50 (60%) 110 (57%) .70
Laboratory data
Glycosylated hemoglobin (%) 5.8%  1.8% 6.1%  2.0% .32
Total cholesterol (mg/dL) 184  37 182  43 .63
Triglycerides (mg/dL) 210  142 202  140 .70
High-density lipoprotein (mg/dL) 43  16 39  12 .08
Low-density lipoprotein (mg/dL) 104  32 112  37 .14
Echocardiographic features
Left atrial diameter (mm) 41.3  6.9 39.2  6.1 .014
LVEDD (mm) 52.1  7.4 51.5  8.0 .60
LVM (g) 205.6  59.3 202.3  75.3 .72
LVM index (g/m2) 119.4  34.8 112.4  38.4 .17
E/e0 ratio 20.3  7.3 11.9  13.8 .002
Diastolic dysfunctionz 40 (47.6%) 65 (33.7%) .03
LVEF (%) 58.1%  13.6% 59.1%  14.2% .58
LVEF<40% 8 (9.5%) 22 (11.4%) .60
CHADS2 score 2.5  1.4 1.7  1.1 <.001
CHA2DS2-VASc score 3.8  1.7 2.5  1.5 <.001
Data are presented as n (%) or mean  SD. POAF, Postoperative atrial fibrillation; TIA, transient ischemic attack; ACEI, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin receptor blockers; LVEDD, left ventricular end-diastolic diameter; LVM, left ventricular mass; E, passive transmitral left ventricular inflow velocity; e0, tissue Doppler
imaging velocity of the medial mitral annulus during passive filling; LVEF, left ventricular ejection fraction. *Vascular disease was defined as previous myocardial infarction,
carotid artery stenosis, or peripheral arterial disease, including previous revascularization, amputation for peripheral arterial disease, or angiographic evidence of peripheral ar-
terial disease. yCarotid artery stenosis was defined as moderate to severe carotid artery stenosis. zDiastolic dysfunction was defined as E/e0 ratio>15.
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log-rank test.RESULTS
Clinical Characteristics and Predictors of POAF
The study population had a mean age of 62 years (range,
38-84 years) and comprised 213 men (77%) and 64 women
(23%). Of the 277 study patients, 213 (79%) had hyperten-
sion, 153 (55%) had diabetes mellitus, 67 (24%) hadThe Journal of Thoracic and Caa history of congestive heart failure, and 38 (14%) had a his-
tory of stroke or TIA. A total of 85 patients (31%) had vas-
cular disease, including 25 with a history of myocardial
infarction, 47 with carotid artery stenosis, and 15 with PAD.
The baseline clinical characteristics of patients with and
without POAF are summarized in Table 1. Of the 277 study
patients, 84 (30%) had POAF at a median of 2 days (range,
0-27 days) after cardiac surgery. The patients with POAF
were older and had a significantly higher prevalence ofrdiovascular Surgery c Volume 146, Number 4 921
TABLE 3. Multivariate logistic regression analysis for postoperative
atrial fibrillation predictors with CHADS2 or CHA2DS2-VASc score
Variable Odds ratio 95% CI P value
With CHADS2 score
Left atrial diameter (mm) 1.02 0.97-1.07 .49
LVMI (g/m2) 1.003 0.99-1.01 .54
E/e0 ratio 1.34 0.76-2.37 .31
LVEF (%) 0.99 0.98-1.02 .87
CHADS2 score 1.54 1.21-1.94 <.001
With CHA2DS2-VASc score
Left atrial diameter (mm) 1.01 0.96-1.06 .59
LVMI (g/m2) 1.002 0.99-1.01 .61
E/e0 ratio 1.42 0.79-2.53 .24
LVEF (%) 0.99 0.98-1.02 .73
CHA2DS2-VASc score 1.63 1.35-1.96 <.001
CI, Confidence interval; LVMI, left ventricular mass index; E, passive transmitral left
ventricular inflow velocity; e0, tissue Doppler imaging velocity of the medial mitral
annulus during passive filling; LVEF, left ventricular ejection fraction.
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Mhypertension and stroke or TIA and vascular disease, in-
cluding previous myocardial infarction and PAD, than the
patients without POAF. The echocardiographic findings of
the patients with POAF included larger left atrial dimen-
sion, higher E/e0 ratio, and higher frequency of E/e0 greater
than 15 than did those obtained for patients without POAF.
There were no significant differences in LVEDD, LVM,
LVM index, and LV ejection fraction between patients
with and without POAF. The patients with POAF had higher
CHADS2 scores (2.5  1.4 vs 1.7  1.1; P< .001) and
CHA2DS2-VASc scores (3.8  1.7 vs 2.5  1.5; P<.001)
than did those without POAF.
Surgical data and postoperative complications are pre-
sented in Table E1. Among a total of 277 study patients, iso-
lated CABG surgery was performed in 258 (93.1%), aortic
valve surgery in 15 (5.4%), tricuspid valve surgery in 1
(0.4%), and combined CABG and valve procedures in 3
(1.1%). The incidences of POAF in the isolated CABG
group and single-valve group were 80 (31.0%) and 4
(25.0%), respectively (P ¼ .61). There were no significant
differences between patients with and without POAF in sur-
gical procure type, rate of on- or off-pump surgery, duration
of bypass or operation, and number of grafts used. In addi-
tion, there were no significant differences in rate of postop-
erative complications between patients with and without
POAF.
Significant predictors of POAF according to univariate
regression analysis are shown in Table 2. CHADS2 score
(OR, 1.62; 95% CI, 1.30-2.02; P < .001), CHA2DS2-
VASc score (OR, 1.67; 95% CI, 1.40-2.01; P<.001), left
atrial diameter (OR, 1.05; 95% CI, 1.01-1.10; P ¼ .02),
and E/e0 ratio (OR, 1.10; 95% CI 1.03-1.17; P ¼ .002)
were significantly associated with POAF. According to
the separate multivariate logistic regression analysis, after
adjustment for echocardiographic risk factors, the CHADS2
(OR, 1.54; 95% CI, 1.21-1.94; P<.001) and CHA2DS2-
VASc scores (OR, 1.63; 95% CI, 1.35-1.96; P < .001)
remained independent predictors of POAF (Table 3).TABLE 2. Univariate regression analysis for postoperative atrial
fibrillation predictors
Variable Odds ratio 95% CI P value
CHADS2 score 1.62 1.30-2.02 <.001
CHA2DS2-VASc score 1.68 1.40-2.01 <.001
ACEIs or ARBs 1.18 0.70-2.01 .52
b-Blockers 0.82 0.47-1.44 .50
Statin therapy 0.75 0.45-1.26 .28
Left atrial diameter (mm) 1.05 1.01-1.10 .02
LVMI (g/m2) 1.005 0.99-1.01 .17
E/e0 ratio 1.10 1.03-1.17 .002
LVEF (%) 0.99 0.98-1.01 .58
CI, Confidence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin receptor blocker; LVMI, left ventricular mass index; E, passive transmitral left
ventricular inflow velocity; e0 , tissue Doppler imaging velocity of the medial mitral
annulus during passive filling; LVEF, left ventricular ejection fraction.
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POAF
The POAF rates after cardiac surgery continuously in-
creased with increasing CHADS2 and CHA2DS2-VASc
scores (Figure 1). Figure E1 shows the OR for predicting
POAF after cardiac surgery on the basis of the CHADS2
and CHA2DS2-VASc scores. The increased POAF risk after
cardiac surgery was magnified with increasing CHADS2
and CHA2DS2-VASc scores.
At the cutoff point of 2, the Kaplan-Meier survival anal-
ysis revealed that patients with CHADS2 scores of at least 2
had a higher POAF rate than did the patients with CHADS2
scores less than 2 (36% vs 20%; P ¼ .005; Figure 2, A).
Furthermore, a CHA2DS2-VASc score of at least 2 also sig-
nificantly predicted the occurrence of events (35% vs 13%;
P ¼ .001; Figure 2, B).CHA2DS2-VASc Scores and POAF in Patients With
CHADS2 Scores of 0 or 1
The subgroup analysis of the 103 patients with CHADS2
scores of 0 or 1 revealed that 21 of these patients (20%) had
POAF. The POAF rate progressively increased from 6% in
patients with CHA2DS2-VASc scores of 0 to 44% in pa-
tients with CHA2DS2-VASc scores of 3 (P ¼ .03;
Figure 3, A). When a CHA2DS2-VASc score of 2 was
used as the cutoff point, the patients with scores of at least
2 were associated with a higher event rate than seen among
the patients with CHA2DS2-VASc scores less than 2 (32%
vs 12%; P ¼ .01; Figure 3, B).Relationship Between CHADS2 or CHA2DS2-VASc
Scores and LV Diastolic Function
The relationship between CHADS2 or CHA2DS2-VASc
scores and LV systolic and diastolic function is summarized
in Table E2. The patients with CHADS2 or CHA2DS2-VAScery c October 2013
FIGURE 1. Postoperative atrial fibrillation (POAF) rates and scores. The POAF rates continuously increased as the CHADS2 (A) and CHA2DS2-VASc
(B) scores increased.
Chua et al Perioperative Managementscores of at least 2 had a larger LA diameter, a higher E/e0
ratio, and a higher rate of E/e0 greater than 15 than did those
with scores less than 2; however, no significant differences
in LVEDD and LV ejection fraction were seen between
these groups.DISCUSSION
Major Findings
This study included a cohort of patients who underwent
cardiac surgery and demonstrated that CHADS2 and
CHA2DS2-VASc scores could be helpful and convenient
scoring systems for predicting POAF after cardiac surgery.
The CHAD2DS2-VASc score was useful in further risk
stratifications for POAF among patients with CHADS2
scores of 0 or 1.FIGURE 2. Postoperative atrial fibrillation (POAF)-free rate curves for patients
Meier survival analysis showed that the patients with CHADS2 scores of at leas
than 2 (log-rank, P<.001; A). In addition, a CHA2DS2-VASc score of at least 2
(log-rank, P<.001; B).
The Journal of Thoracic and CaIncidence of New-Onset POAFAfter Cardiac
Surgery
Similar to the results of earlier studies, the incidence of
POAF in this study was 30% at a median of 2 days (range,
0-27 days) after cardiac surgery.1,2CHADS2 and CHA2DS2-VASc Scores and POAF
After Cardiac Surgery
To date, several demographic and preoperative factors
such as age, sex, hypertension, diabetes mellitus, and LV
systolic and diastolic function have been shown to be risk
factors for POAF4,6; however, no published classification
scheme has included these risk factors to estimate the risk
of POAF in patients who undergo cardiac surgery. With
different multivariate models, our study demonstrated thatwith higher and lower CHADS2 and CHA2DS2-VASc scores. The Kaplan-
t 2 had a higher event rate than did the patients with CHADS2 scores lower
also significantly predicted occurrences of postoperative atrial fibrillation
rdiovascular Surgery c Volume 146, Number 4 923
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FIGURE 3. A, Postoperative atrial fibrillation (POAF) rates in the patients
with CHADS2 scores of 0 or 1. Postoperative atrial fibrillation rates pro-
gressively increased from 6% to 44% with increasing CHA2DS2-VASc
score. B, Flowchart of postoperative atrial fibrillation rates and scores.
This flowchart demonstrates the postoperative atrial fibrillation rates in
the patients stratified according to CHADS2 and CHA2DS2-VASc scores.
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cardiac surgery. These finding extend the usefulness of
CHADS2 scores to the prediction of POAF in patients
undergoing cardiac surgery. Physicians and patients could
use these scores to make decisions about prophylactic
therapy according to patient-specific POAF risk.
In our study, POAF rates increased with increasing
CHA2DS2-VASc score, whereas patients with scores of
0 to 1 had low POAF rates. The CHA2DS2-VASc score
could further stratify the patients with CHADS2 scores of
0 or 1 into 2 groups with different POAF risks at the cutoff
value of 2. There is some justification for the addition of fe-
male sex, vascular disease, and age 65 to 74 years into the
combination risk factor category in the CHA2DS2-VASc
score. The impact of female sex on atrial arrhythmia has re-
cently been reviewed.23,24 In all age groups, men have
a higher incidence of AF than do women. Because the
incidence of AF increases with age and there are more
women in the population who are older than 65 years, the924 The Journal of Thoracic and Cardiovascular Surgabsolute numbers of female and male patients with AF in
this age group are equal.23,24
The impact of vascular disease, particularly myocardial
infarction, on increasing AF risk has also been systemati-
cally reviewed. AF often complicates myocardial infarc-
tion, with an incidence of 6% to 21%. Furthermore, the
presence of AF in association with PAD is associated with
substantial mortality and morbidity.25 Because age does
not have a binary effect on AF and an age of at least 75 years
is a high risk factor, an age of 65 to 74 years plus an addi-
tional combination risk factor increases risk of AF.23 Taken
together, the risk of new-onset AF after cardiac surgery
might increase with the combination of these additional
risk factors in the CHA2DS2-VASc score.
Potential Mechanisms Responsible for the
Association Between Increased CHADS2 or
CHA2DS2-VASc Scores and POAF
Because it is well established that atrial dilatation and
stretch increase atrial vulnerability to the occurrence of
AF, it has been reported that increasing LV diastolic dys-
function is strongly correlated with left atrial enlarge-
ment.26 An incremental deterioration of diastolic function
is associated with increased left atrial dimension and pro-
vides further predictive information with regard to the oc-
currence of POAF.5,26,27 Each component of the CHADS2
and CHA2DS2-VASc scores was associated with
ventricular remodeling and LV diastolic function that may
lead to left atrial enlargement.13,14 In addition, this study
also found that patients with CHADS2 and CHA2DS2-
VASc scores of at least 2 had worse LV diastolic function
than did those with scores lower than 2. These findings
suggest that advanced CHADS2 and CHA2DS2-VASc
score amplifies the POAF risk after cardiac surgery and
that these changes are mediated by stress on the atria in
the context of impaired LV diastolic function to increase
the risk of POAF.
Clinical Implications
Several studies have demonstrated that interventions to
prevent POAF consisting of b-blockers, amiodarone, or sta-
tins are favored with respect to clinical outcome8,9;
however, these studies did not provide a useful scoring
system to discriminate patients at a high risk for POAF.
According to this study, the CHADS2 scoring system is
a simple tool that can predict new-onset POAF after cardiac
surgery. A CHADS2 score of at least 2 was associated with
a 36% risk of POAF. Furthermore, the more detailed
CHA2DS2-VASc scoring system can further discriminate
patients at risk for POAF among patients with CHADS2
scores of 0 or 1. The clinical implication of CHA2DS2-
VASc scores should be emphasized, because patients with
CHADS2 scores of 0 or 1 have traditionally been assumed
to be at low risk; however, those with CHA2DS2-VAScery c October 2013
Chua et al Perioperative Managementscores of 3 can have a POAF rate as high as 44%. These
findings demonstrate the important role of the CHA2DS2-
VASc scores in discriminating supposedly low-risk patients
who are at risk for POAF and optimizing preoperative man-
agement of antiarrhythmic therapy before cardiac surgery is
prescribed to lower the risk. A further large-scale, prospec-
tive trial is necessary to prove this supposition.Study Limitations
There are several limitations to the interpretation of our
study. The incidence of POAF may be different among pa-
tients undergoing CABG and valve procedures, and thus the
application of the scoring system to a nonhomogeneous
group of patients may have biased the results. Most of the
study patients underwent isolated CABG or a single-valve
operation, however, and only a few proportionately of
them underwent both CABG and valve surgery. Previous
studies as well as our own have shown that the incidence
of POAF does not differ significantly between patients un-
dergoing isolated CABG and those undergoing single-valve
procedures.5
The patients were not monitored with a continuous re-
cording system for 30 days after cardiac surgery. It is there-
fore possible that short arrhythmic episodes were missed. In
addition, any participants with paroxysmal or asymptom-
atic AF were missed if such episodes occurred outside of
the hospital. The incidence of POAF in this study thus
may be underestimated, which would have biased the re-
sults and worked against the significant association among
CHADS2 and CHA2DS2-VASc scores and POAF. Our find-
ings resemble those of earlier studies, however, in that the
peak incidence of POAF was between postoperative days
2 and 4.4,5P
MCONCLUSIONS
CHADS2 and CHA2DS2-VASc scores can provide an es-
timate of the POAF risk in patients who undergo cardiac
surgery. Among patients with CHADS2 scores of 0 or 1,
CHA2DS2-VASc scores were helpful to discriminate further
which patients were predisposed toward increased POAF
risk.
We thank Ching-Yin Yeh of the Graduate Institute of Public
Health, Taipei Medical University, for her support in performing
the statistical analyses.References
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FIGUREE1. Adjusted odds ratios of CHADS2 or CHA2DS2-VASc scores
for predicting postoperative atrial fibrillation after cardiac surgery. The pa-
tients with increased CHADS2 or CHA2DS2-VASc scores face a progres-
sively increasing risk of postoperative atrial fibrillation with each
subsequent increment in score. The odds ratio is defined as the likelihood
of postoperative atrial fibrillation after cardiac surgery compared with
scores of 0. *P<.05 compared with CHADS2 score of 0. yP<.05 com-
pared with CHA2DS2-VASc score of 0.
TABLE E1. Surgical procedure and postoperative complications of
patients with and without postoperative atrial fibrillation
With POAF
(n ¼ 84)
Without POAF
(n ¼ 193) P value
Surgical procedure .59
Isolated CABG 80 (95.2%) 178 (92.2%)
Aortic valve procedures 4 (4.8%) 11 (5.7%)
Tricuspid valve procedures 0 (0%) 1 (0.5%)
Combined CABG and
valve surgery
0 (0%) 3 (1.6%)
Bypass surgery .80
On-pump surgery 57 (67.9%) 1301 (67.9%)
Off-pump surgery 27 (32.%1) 62 (32.1%)
Duration of bypass (min) 123  65 124  62 .89
Duration of operation (min) 300  125 307  107 .64
Grafts used .65
1 6 (7.1%) 7 (3.6%)
2 8 (9.5%) 18 (9.3%)
3 65 (77.4%) 156 (80.8%)
Postoperative complications
Poor wound healing
requiring reconstruction
6 (7.1%) 6 (3.2%) .15
Stroke 4 (4.8%) 5 (2.7%) .38
Sepsis 2 (2.4%) 3 (1.6%) .67
Massive gastrointestinal
bleeding
2 (2.4%) 3 (1.6%) .67
Myocardial infarction 1 (1.2%) 1 (0.5%) .57
Acute renal failure
requiring hemodialysis
1 (1.2%) 1 (0.5%) .57
Data are presented as n (%) or mean  SD. POAF, Postoperative atrial fibrillation;
CABG, coronary artery bypass grafting.
TABLE E2. Echocardiographic features of the different CHADS2 and
CHA2DS2-VASc scores (<2 and 2)
<2 2 P value
CHADS2 score
Left atrial diameter (mm) 38.3  6.3 40.7  6.3 .002
LVEDD (mm) 50.8  7.8 52.2  7.8 .15
LVM (g) 197.6  77.5 209.4  71.2 .21
LVM index (g/m2) 110.8  43.7 122.8  45.3 .04
E/e0 ratio 10.1  8.2 21.6  11.6 <.001
E/e0 ratio>15 28 (27%) 77 (44%) .005
LVEF (%) 60.5%  12.3% 57.2%  14.7% .08
CHA2DS2-VASc score
Left atrial diameter (mm) 38.3  5.7 40.3  6.5 .04
LVEDD (mm) 50.1  7.4 52.1  7.9 .08
LVM (g) 187.2  63.7 209.8  75.5 .04
LVM index (g/m2) 103.2  36.3 122.6  46.3 .004
E/e0 ratio 10.0  7.2 18.8  12.2 .003
E/e0 ratio>15 15 (25%) 90 (41%) .026
LVEF (%) 61.2%  12.0% 58.2%  14.5% .15
LVEDD, Left ventricular end diastolic diameter; LVM, left ventricular mass; E, pas-
sive transmitral left ventricular inflow velocity; e0, tissue Doppler imaging velocity of
the medial mitral annulus during passive filling; LVEF, left ventricular ejection
fraction.
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